A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

drug protocol number
CABL001A2301
drug sponsor
Novartis
drug study
ABL001 (asciminib)
drug trial site
KFSH&RC-R
drug status
Ongoing
drug phase